Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.47 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.47 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.47 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7620776 | 1.00 | HDAC3 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7615412 | 1.00 | HDAC3 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9056155 | 0.93 | S1PR2 (0.46) | HDAC1LTB4RS1PR2S1PR4S1PR1 | |
| SCHEMBL4661178 | 0.93 | HDAC3 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8463990 | 0.91 | HDAC3 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7613532 | 0.91 | S1PR2 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7616376 | 0.91 | S1PR2 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4662607 | 0.90 | ACACB (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7623903 | 0.89 | PLAAT3 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3676720 | 0.86 | HDAC3 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3199203-B1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS INC (US) | 2020-02-05 | — | — | EP | claimed |
| EP-1772149-A1 | DRUG FOR PREVENTION OR TREATMENT OF DIABETES | Kowa Company. Ltd. (JP) | 2007-04-11 | — | — | EP | claimed |
| EP-1752147-A1 | DRUG FOR PREVENTION OR TREATMENT OF DIABETES | Kowa Company Ltd. (JP) | 2007-02-14 | — | — | EP | claimed |
| EP-1747780-A1 | DRUG FOR PREVENTION OR TREATMENT OF DIABETES | KOWA COMPANY, LTD. (JP) | 2007-01-31 | — | — | EP | claimed |
| US-20060051410-A1 | Pharmaceutical composition containing 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid | KOWA COMPANY, LTD. (JP) | 2006-03-09 | — | — | US | claimed |
| US-20060025478-A1 | Medicine for prevention or treatment of diabetes | KOWA COMPANY, LTD. (JP) | 2006-02-02 | — | — | US | claimed |
| US-20050272814-A1 | Medicine for prevention or treatment of diabetes | KOWA COMPANY, LTD. (JP) | 2005-12-08 | — | — | US | claimed |
| US-20050261349-A1 | Medicine for prevention or treatment of diabetes | KOWA COMPANY, LTD. (JP) | 2005-11-24 | — | — | US | claimed |
| EP-1473033-A1 | MEDICINAL COMPOSITION CONTAINING 2,2-DICHLORO-12-(4-CHLOROPHENYL)DODECANOIC ACID | Kowa Company Ltd. (JP) | 2004-11-03 | — | — | EP | claimed |
| EP-0790824-B1 | 2,2-DICHLOROALKANE CARBOXYLIC ACIDS, PROCESS FOR PREPARING THE SAME, MEDICAMENT CONTAINING THE SAME, AND USE THEREOF FOR TREATING INSULIN RESISTANCE | ROCHE DIAGNOSTICS GMBH (DE) | 2002-02-06 | — | — | EP | claimed |
| US-5968982-A | TREATMENT OF DIABETES | ROCHE DIAGNOSTICS GMBH (DE) | 1999-10-19 | — | — | US | claimed |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | CYMABAY THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190192475-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20030045553-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | ORTHO-MCNEIL PHARMACEUITCAL, INC. | 2003-03-06 | — | — | US | disclosed |
| EP-0790824-B1 | 2,2-DICHLOROALKANE CARBOXYLIC ACIDS, PROCESS FOR PREPARING THE SAME, MEDICAMENT CONTAINING THE SAME, AND USE THEREOF FOR TREATING INSULIN RESISTANCE | ROCHE DIAGNOSTICS GMBH (DE) | 2002-02-06 | — | — | EP | disclosed |
| US-5968982-A | TREATMENT OF DIABETES | ROCHE DIAGNOSTICS GMBH (DE) | 1999-10-19 | — | — | US | disclosed |
| EP-0790824-A1 | 2,2-DICHLOROALKANE CARBOXYLIC ACIDS, PROCESS FOR PREPARING THE SAME, MEDICAMENT CONTAINING THE SAME, AND USE THEREOF FOR TREATING INSULIN RESISTANCE | Roche Diagnostics GmbH (DE) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015784-A2 | 2,2-DICHLOROALKANE CARBOXYLIC ACIDS, PROCESS FOR PREPARING THE SAME, MEDICAMENT CONTAINING THE SAME, AND USE THEREOF FOR TREATING INSULIN RESISTANCE | BOEHRINGER MANNHEIM GMBH (DE) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | HDAC3 96/4885HDAC4 293/4885HDAC1 308/4885 |
| US-20190192475-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | HDAC3 83/4885HDAC4 230/4885HDAC1 445/4885 |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | HDAC3 83/4885HDAC4 230/4885HDAC1 445/4885 |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | LDLR, APOB, HDLBP | HDAC3 96/4885HDAC4 293/4885HDAC1 308/4885 |
| US-20030045553-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | GPR119, SLC2A4, PPARG | HDAC3 938/4885HDAC4 996/4885HDAC1 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.